What's the price of TherapeuticsMD (txmd) stock?
TherapeuticsMD's stock was trading at $0.3035 at the start of the year. Since then, TXMD stock has increased by 3,168.5% and is now trading at $9.92. View the best growth stocks for 2022 here. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NYSE:TXMD) posted its quarterly earnings data on Monday, May, 16th.
What is TherapeuticsMD's stock symbol?
What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by a variety of institutional and retail investors.
When is TherapeuticsMD's next quarterly earnings announcement?
TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022. View our earnings forecast for TherapeuticsMD. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings results on Thursday, November, 11th.
Will txmd outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe TXMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
See more
Is TXMD stock a good buy?
TherapeuticsMD Inc (NASDAQ:TXMD) The 1 analysts offering 12-month price forecasts for TherapeuticsMD Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +40.06% increase from the last price of 7.14.
Will TXMD be bought out?
(RTTNews) - Women's healthcare company TherapeuticsMD, Inc. (TXMD), on Tuesday announced that it has entered into a definitive merger agreement, to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in healthcare companies.
Why is TXMD stock going down?
TXMD has received a notice of continued listing standard letter from Nasdaq, notifying it that it had failed to meet Nasdaq's minimum bid price criterion. In addition, its widening losses and negative profit margin continue to threaten its future price performance.
Is TXMD doing a reverse split?
The Company expects that the effective time of the Reverse Stock Split will be on or about 5:00 pm New York time on Friday, May 6, 2022, with the Common Stock trading on a post-split basis under the Company's existing trading symbol, “TXMD,” at the market open on Monday, May 9, 2022.
Will TXMD go up?
Analyst Price Target on TXMD Based on 2 Wall Street analysts offering 12 month price targets for TherapeuticsMD in the last 3 months. The average price target is $5.50 with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a -41.98% change from the last price of $9.48.
Is TXMD being shorted?
Short Shares Availability This table shows the number of shares of US:TXMD available to be shorted at a leading prime brokerage.
What is TXMD working on?
(NASDAQ: TXMD), an innovative women's healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the Company's investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia ...
Is CEI a good investment?
Is CEI stock a good investment? The short answer is no, CEI stock is not a good investment. It is a penny stock and the recent attention around the company is purely hype. CEI is also classed as a meme stock, which means it is subject to severe volatility.
Will CEI stock go up?
Based on the algorithm-based CEI price prediction from Wallet Investor as of 22 March, the price of Camber Energy in the near term could rise to $1.14 per share by 4 April 2022.
What does a 1 for 4 reverse stock split mean?
In a 1-for-4 split, a shareholder of four shares will end up with one share. The price of one share will be the sum of all the four shares, enhancing the per-share value. The market capitalization value remains the same as there are no new additions, only a restructuring.
What is a 1 for 50 reverse stock split?
At the effective time of the reverse stock split, every fifty (50) shares of Diffusion's issued, and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.001 per share or the total number of authorized shares.
What is a reverse split on stocks?
A reverse stock split occurs when a publicly traded company divides the number of outstanding shares by a certain amount. This serves to decrease the number of outstanding shares and increase the price per share of those outstanding shares.
Should I buy or sell TherapeuticsMD stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are curr...
What is TherapeuticsMD's stock price forecast for 2022?
3 equities research analysts have issued 12-month price targets for TherapeuticsMD's shares. Their forecasts range from $125.00 to $250.00. On aver...
How has TherapeuticsMD's stock performed in 2022?
TherapeuticsMD's stock was trading at $17.7750 at the beginning of the year. Since then, TXMD shares have decreased by 44.0% and is now trading at...
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest in May. As of May 31st, there was short interest totaling 2,010,000 shares, an increase of 36.7% fr...
When is TherapeuticsMD's next earnings date?
TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Ther...
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its earnings results on Monday, May, 16th. The company reported ($5.69) earnings per share (EPS) for t...
When did TherapeuticsMD's stock split? How did TherapeuticsMD's stock split work?
TherapeuticsMD's stock reverse split on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares ow...
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the following people: Mr. Robert G. Finizio , Co-Founder (Age 51, Pay $1.22M) ( LinkedIn Profile ) Dr....
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Esperion Therapeutics (ESPR) , OrganiGram (OGI) , Radius Health (RDUS) , Generation B...
Recently Viewed Tickers
TherapeuticsMD Inc
Visit a quote page and your recently viewed tickers will be displayed here.
What is TherapeuticsMD's ticker symbol?
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
What is TherapeuticsMD?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How much does TherapeuticsMD make?
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
What is the P/E ratio of TherapeuticsMD?
TherapeuticsMD has a market capitalization of $408.92 million and generates $64.87 million in revenue each year. The company earns $-183,520,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.
Does TherapeuticsMD pay dividends?
The P/E ratio of TherapeuticsMD is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
